Evident Vascular launches with $35M for AI-enabled intravascular ultrasound

Evident Vascular, a company pioneering AI-enhanced intravascular ultrasound technology, has unveiled its launch today, backed by a substantial $35 million in Series A funding. Leading this funding round is Vensana Capital.

Headquartered in California, Evident Vascular has engineered AI-infused transcatheter intravascular ultrasound technology. This groundbreaking innovation allows for the capture of images within a patient's blood vessels, facilitating the assessment of vascular conditions and enhancing the interpretation of these images.

Cynthia Yee, Principal at Vensana Capital, expressed her enthusiasm for this venture, stating, "While substantial progress has been made in treating peripheral vascular diseases, the tools necessary for precise and well-guided delivery of these therapies have been lacking. We recognize a significant opportunity to develop a next-generation IVUS platform that caters to the requirements of vascular interventionists, and we are thrilled to collaborate with an exceptional team in launching Evident Vascular."

Intravascular ultrasound represents a critical imaging modality employed in interventional cardiology, enabling the acquisition of comprehensive 360-degree images from within a patient's artery. This technology's objective is to offer a more comprehensive view of blood vessels compared to traditional angiography, which relies on X-rays to provide two-dimensional external views of blood vessels.

Evident Vascular has disclosed that its technology is initially tailored for peripheral vascular interventions. Nonetheless, the company harbors ambitions to broaden its capabilities to encompass coronary procedures in the future.

Click here to read the original news story.